Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18704718 | SYSTEMS AND METHODS FOR INCREASED PRODUCTION OF RECOMBINANT BIOPOLYMERS VIA GENOME ENGINEERING AND DOWNREGULATION OF BASAL EXPRESSION | April 2024 | March 2025 | Allow | 10 | 2 | 1 | Yes | No |
| 18538064 | TESTING FOR PARTICULATES | December 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18449994 | METHODS AND COMPOSITIONS FOR SELECTIVE CLEAVAGE OF NUCLEIC ACIDS WITH RECOMBINANT NUCLEASES | August 2023 | June 2025 | Allow | 22 | 2 | 1 | No | No |
| 18108119 | TESTING FOR PARTICULATES | February 2023 | November 2023 | Allow | 9 | 2 | 1 | Yes | No |
| 18079222 | TESTING FOR PARTICULATES | December 2022 | November 2023 | Allow | 11 | 3 | 1 | Yes | Yes |
| 17955537 | YEAST-BASED IMMUNOTHERAPY AGAINST CLOSTRIDIUM DIFFICILE INFECTION | September 2022 | April 2025 | Allow | 30 | 1 | 0 | No | No |
| 17930483 | COMPOSITIONS AND METHODS RELATING TO STRUCTURAL DETERMINATION OF SMALL PROTEINS | September 2022 | April 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 17809588 | P AERUGINOSA PCRV-LINKED ANTIGEN VACCINES | August 2022 | October 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17797055 | RECOMBINANT THERAPEUTIC INTERVENTIONS FOR CANCER | August 2022 | March 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17868571 | POULTRY DRINKING WATER-BASED VACCINE DELIVERY SYSTEM AND METHOD | July 2022 | June 2025 | Allow | 35 | 2 | 1 | No | No |
| 17788549 | BREAST MILK-DERIVED LACTOBACILLUS PLANTARUM AND USE THEREOF | June 2022 | May 2025 | Allow | 35 | 1 | 0 | No | No |
| 17748984 | TARGETING NAPA-LINKED PEPTIDOGLYCAN FOR TREATING LYME DISEASE | May 2022 | December 2024 | Abandon | 31 | 2 | 1 | Yes | No |
| 17657159 | NEUROTOXINS FOR USE IN MINIMIZING SCARRING | March 2022 | September 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17763014 | ORAL ADMINISTRATION OF GENETICALLY ENGINEERED BACTERIA | March 2022 | May 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17641841 | Method for diagnosis of lung disease based on antibodies for microbial-derived vesicles | March 2022 | April 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17670565 | METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN | February 2022 | March 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17670408 | New Core/Shell Materials of Nanowire/Graphene on Low-Cost RFID Tags for Rapidly Sensing Live Cell Metabolites at Single-Cell Sensitivity | February 2022 | November 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17588910 | FEED SUPPLEMENT | January 2022 | May 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17579006 | BACTERIA | January 2022 | June 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17573193 | Bacteriocin Production, Compositions and Methods of Use | January 2022 | January 2025 | Abandon | 37 | 3 | 0 | No | No |
| 17567623 | IMMUNOLOGICAL SIGNATURES AND PARAMETERS PREDICTING THERAPEUTIC RESPONSES TO ANTI-TNF THERAPY | January 2022 | June 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17557939 | LACTOBACILLUS COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF MICROBIAL INFECTION | December 2021 | February 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17555867 | PRODUCTION OF SQUALENE FROM HYPER-PRODUCING YEASTS | December 2021 | March 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17551882 | Method and process to make chitosan-doped strontium oxide nanocomposite for bactericidal applications | December 2021 | January 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17541365 | COMPOSITIONS AND METHODS OF DETERMINING A LEVEL OF INFECTION IN A SUBJECT | December 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17532217 | Triple Vaccine for Diseases Caused by Salmonella typhimurium, Riemerella anatipestifer and Escherichia coli | November 2021 | November 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17527488 | TREATMENT OF CANCER USING RECALL ANTIGENS DELIVERED BY ATTENUATED BACTERIA | November 2021 | July 2023 | Abandon | 20 | 4 | 0 | No | No |
| 17594107 | COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIUM DIFFICILE | October 2021 | June 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17599101 | PNEUMOCOCCAL SURFACE PROTEINS | September 2021 | February 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17472936 | MUTANT TRANSPORTERS FOR BACTERIAL UPTAKE OF TEREPHTHALIC ACID | September 2021 | April 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17433103 | TUMOR-DELIVERED MULTI-TARGET THERAPEUTICS FOR COLON CANCER | August 2021 | October 2022 | Allow | 14 | 1 | 1 | Yes | No |
| 17430137 | ANTISENSE OLIGOMERS FOR CONTROLLING CANDIDA ALBICANS INFECTIONS | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17429089 | STREPTOCOCCUS PNEUMONIAE ANTISERUM WITHOUT CROSS-REACTIVITY AND METHOD FOR PRODUCING THE SAME | August 2021 | December 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17356300 | BOTULINUM TOXIN PREFILLED CONTAINER | June 2021 | June 2025 | Allow | 48 | 1 | 0 | No | No |
| 17349960 | BACILLUS SUBTILIS BS40-4 STRAIN AND METHOD FOR COMPOSTING ORGANIC WASTES BY USING THE SAME | June 2021 | June 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17312887 | NITROCELLULOSE SHEET COMPRISING IMMOBILIZED IMMUNOGLOBULINS AND LIPID BASED ANTIGENS AND USE THEREOF | June 2021 | April 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17335573 | SUBUNIT VACCINE OF CONTAGIOUS CAPRINE PLEUROPNEUMONIA AND PREPARATION METHOD AND USE THEREOF | June 2021 | August 2023 | Allow | 26 | 2 | 1 | Yes | No |
| 17242635 | CANINE MICROBE PREPARATIONS FOR INCREASING OXYTOCIN | April 2021 | December 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17288060 | DETECTION OF BIOLOGICALS PENETRATION INTO TISSUE SURROGATES | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17233901 | USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED ACUTE RESPIRATORY DISTRESS | April 2021 | September 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17286453 | Live Biotherapeutics to Treat and Prevent Lung Conditions | April 2021 | July 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17272640 | METHOD FOR REDUCING THE TRANSFER OF PATHOGENIC MICROORGANISMS | March 2021 | August 2024 | Allow | 41 | 4 | 1 | Yes | No |
| 17271356 | RECOMBINANT MICROORGANISM, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PRODUCING COENZYME Q10 | February 2021 | September 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17176513 | IMMUNE-ENHANCED AQUACULTURE | February 2021 | February 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17261345 | VACCINE FORMULATIONS COMPRISING PRESERVATIVE | January 2021 | March 2025 | Allow | 50 | 5 | 0 | Yes | No |
| 17141104 | BIFIDOBACTERIUM ANIMALIS AND APPLICATION OF COMPOUND BACTERIUM PREPARATION PREPARED FROM BIFIDOBACTERIUM ANIMALIS IN PREPARING MEDICINE FOR TREATING OR PREVENTING AVIAN INFLUENZA VIRUS INFECTION | January 2021 | July 2023 | Allow | 30 | 1 | 1 | No | No |
| 17126396 | METHODS AND COMPOSITIONS RELATED TO SOLUBLE MONOCLONAL VARIABLE LYMPHOCYTE RECEPTORS OF DEFINED ANTIGEN SPECIFICITY | December 2020 | November 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16951906 | Method for the preparation of an anti-streptococcus serum for use in the treatment of human streptococcus-related diseases. | November 2020 | December 2023 | Abandon | 37 | 1 | 0 | Yes | No |
| 17088547 | LIPIDATED PSA COMPOSITIONS AND METHODS | November 2020 | July 2023 | Allow | 33 | 3 | 1 | Yes | No |
| 17082668 | Bacteroides fragilis for Relieving Endotoxin Infection and Application Thereof | October 2020 | January 2023 | Allow | 27 | 1 | 0 | No | No |
| 17073817 | CLAUDIN-TARGETING AGENTS AND USES THEREOF | October 2020 | April 2024 | Allow | 42 | 3 | 1 | Yes | No |
| 17028768 | Algal extract comprising sulphated and non-sulphated polyanionic polysaccharides and uses thereof | September 2020 | January 2023 | Allow | 27 | 2 | 0 | No | No |
| 16982888 | Anti-Stress Composition | September 2020 | March 2023 | Allow | 30 | 2 | 1 | Yes | No |
| 16987998 | Multivalent VLP Conjugates | August 2020 | August 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16945278 | System and Method of Automatically Preparing and Analyzing Urine Samples for Identifying Cancer Cells | July 2020 | September 2024 | Abandon | 49 | 1 | 0 | No | No |
| 16942980 | METHOD OF TREATING AN EYE DISORDER BY INHIBITING OR DISRUPTING BACTERIAL BIOFILM FORMATION | July 2020 | November 2024 | Abandon | 52 | 7 | 0 | No | No |
| 16939100 | VMP-LIKE SEQUENCES OF PATHOGENIC BORRELIA SPECIES AND STRAINS | July 2020 | November 2023 | Abandon | 39 | 3 | 1 | No | No |
| 16955541 | Reactors and Submerged Fermentation Methods for Producing Microbe-Based Products | June 2020 | August 2024 | Allow | 50 | 1 | 1 | Yes | No |
| 16642696 | DETECTION METHOD AND DETECTION PROBE FOR COLIBACTIN AND COLIBACTIN-PRODUCING BACTERIA | June 2020 | January 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16850143 | METHODS AND COMPOSITIONS EMPLOYING IMMUNOGENIC FUSION PROTEINS | April 2020 | February 2023 | Allow | 34 | 1 | 1 | No | No |
| 16832561 | Species of Genus Pholiota and Artificial Cultivation Method and Use Thereof | March 2020 | April 2023 | Abandon | 36 | 2 | 1 | No | No |
| 16645225 | IMMUNE FUNCTION EVALUATION METHOD AND ELISA SYSTEM THEREFOR | March 2020 | March 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16790161 | RECOMBINANT THERAPEUTIC INTERVENTIONS FOR CANCER | February 2020 | July 2021 | Abandon | 17 | 1 | 0 | No | No |
| 16638595 | METHODS OF BOOSTING IMMUNE RESPONSES | February 2020 | March 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16787785 | ENVIRONMENTAL PROFICIENCY METHODS IN A FOOD PRODUCTION ENVIRONMENT | February 2020 | August 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16636251 | INDUCTION OF PROTECTIVE IMMUNITY AGAINST ANTIGENS | February 2020 | August 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16750985 | THERAPEUTIC AND PROPHYLACTIC TREATMENT FOR COLORECTAL CANCER | January 2020 | September 2022 | Allow | 32 | 2 | 1 | Yes | No |
| 16631964 | VACCINES AGAINST TICK-BORNE DISEASES | January 2020 | May 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16704777 | COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF | December 2019 | August 2022 | Allow | 32 | 1 | 1 | No | No |
| 16617691 | COMPOSITION CONTAINING MICROORGANISMS DERIVED FROM LIVING BODY AND METHOD FOR MANUFACTURING THE SAME | November 2019 | February 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 16692265 | METHOD OF IMPROVING UROGENITAL HEALTH USING PROBIOTIC BACTERIA | November 2019 | March 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16615760 | COMPOSITIONS AND METHODS FOR DECREASING A POPULATION OF BILOPHILA WADSWORTHIA OR INHIBITING THE GROWTH THEREOF | November 2019 | March 2024 | Abandon | 52 | 4 | 1 | No | No |
| 16609705 | METHODS AND COMPOSITIONS FOR SELECTIVE CLEAVAGE OF NUCLEIC ACIDS WITH RECOMBINANT NUCLEASES | October 2019 | June 2023 | Allow | 43 | 1 | 1 | Yes | No |
| 16608651 | ANALYTICAL AND THERAPEUTIC METHODS AND COMPOSITIONS, AND USES THEREOF | October 2019 | February 2024 | Abandon | 52 | 4 | 1 | No | No |
| 16661789 | METHOD AND COMPOSITION FOR TREATMENT OF HYPERGLYCEMIA | October 2019 | February 2021 | Allow | 16 | 1 | 0 | No | No |
| 16480169 | FINDING AND TREATMENT OF INFLAMMATION AFTER BIRTH IN CHIMERIC ANIMAL | October 2019 | August 2023 | Allow | 49 | 2 | 1 | Yes | No |
| 16604866 | METHODS OF TREATING AND DIAGNOSING IBD ASSOCIATED WITH R. GNAVUS AND/OR R. GNAVUS GROUP IBD COLONIZATION | October 2019 | June 2023 | Allow | 44 | 3 | 0 | Yes | No |
| 16500934 | RECOMBINANT BCG OVEREXPRESSSING phoP-phoR | October 2019 | February 2023 | Allow | 40 | 4 | 1 | Yes | No |
| 16574954 | HYPERIMMUNIZED EGG PRODUCT FOR TREATMENT OF NECROTIC ENTERITIS IN POULTRY | September 2019 | September 2021 | Allow | 24 | 2 | 0 | Yes | No |
| 16494947 | ENTERIC FEVER VACCINE BASED ON OUTER MEMBRANE VESICLES FROM TWO DIFFERENT STRAINS OF TYPHOIDAL SALMONELLE SPECIES | September 2019 | August 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16342992 | Composition For Treating Fulminant Acute Pneumonia Including CD69 Antagonist | September 2019 | February 2023 | Allow | 46 | 4 | 0 | Yes | Yes |
| 16489853 | TESTING FOR PARTICULATES | August 2019 | November 2022 | Allow | 38 | 3 | 0 | Yes | No |
| 16081984 | Immunochromatographic Device | August 2019 | June 2023 | Allow | 58 | 1 | 1 | Yes | No |
| 16484798 | MODIFIED NANOPORES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | August 2019 | July 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16514796 | Probiotic Prevention and Treatment of Colon Cancer | July 2019 | April 2020 | Allow | 9 | 1 | 0 | No | No |
| 16460993 | MESOTHELIN VACCINES AND MODEL SYSTEMS | July 2019 | November 2021 | Allow | 29 | 1 | 1 | Yes | No |
| 16474647 | A NON-HUMAN ANIMAL MODEL OF NEURODEGENERATIVE DISORDERS | June 2019 | October 2022 | Abandon | 39 | 0 | 1 | No | No |
| 16471761 | DEVICES AND METHODS FOR WOUND TREATMENT | June 2019 | June 2024 | Abandon | 59 | 2 | 1 | No | Yes |
| 16468982 | HUMAN GENETIC MARKERS ASSOCIATED WITH RESPONSE TO TREATMENTS THAT TARGET CLOSTRIDIUM DIFFICILE TOXIN B | June 2019 | March 2024 | Allow | 57 | 4 | 0 | Yes | No |
| 16468343 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | June 2019 | August 2022 | Abandon | 39 | 1 | 1 | No | No |
| 16467934 | NOVEL PROBIOTICS BIFIDOBACTERIA STRAINS | June 2019 | November 2022 | Allow | 41 | 3 | 1 | Yes | No |
| 16465237 | EXOPOLYSACCHARIDES AND USES THEREOF | May 2019 | May 2022 | Allow | 36 | 1 | 1 | Yes | No |
| 16422336 | VACCINE CANDIDATES AGAINST JOHNE'S DISEASE | May 2019 | April 2024 | Allow | 59 | 4 | 1 | Yes | No |
| 16463704 | EX VIVO ANTIGEN AND ADJUVANT PULSED PERIPHERAL BLOOD MONONUCLEAR CELLS AS A SCREENING PLATFORM FOR CANDIDATE NOVEL VACCINES AND CANDIDATE ANTIGENS | May 2019 | May 2022 | Allow | 36 | 3 | 0 | Yes | No |
| 16463364 | PNEUMOCOCCAL VACCINE COMBINING SELECTED ALPHA HELICAL DOMAINS AND PROLINE RICH DOMAINS OF PNEUMOCOCCAL SURFACE PROTEIN A | May 2019 | June 2023 | Allow | 49 | 2 | 2 | Yes | Yes |
| 16462392 | LARVICIDE COMPOSITIONS AND METHODS | May 2019 | March 2022 | Allow | 34 | 1 | 1 | Yes | No |
| 16461326 | CHIMERIC ANTIBODIES COMPRISING BINDING DOMAINS OF PHAGE LYSINS, BACTERIAL AUTOLYSINS, BACTERIOCINS, AND PHAGE TAIL OR TAIL FIBERS | May 2019 | December 2021 | Abandon | 31 | 1 | 1 | No | No |
| 16347407 | Bacteriocin Production, Compositions and Methods of Use | May 2019 | September 2021 | Allow | 29 | 1 | 1 | Yes | No |
| 16347321 | BIOTHIOL DETECTION COMPOSITION COMPRISING REDOX REGULATION PROTENIN | May 2019 | July 2022 | Abandon | 38 | 1 | 1 | No | No |
| 16396876 | MODULATION OF IMMUNE FUNCTION BY BACILLUS COAGULANS | April 2019 | January 2022 | Allow | 32 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHAHNAN SHAH, KHATOL S.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 31.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SHAHNAN SHAH, KHATOL S works in Art Unit 1645 and has examined 518 patent applications in our dataset. With an allowance rate of 55.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner SHAHNAN SHAH, KHATOL S's allowance rate of 55.2% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SHAHNAN SHAH, KHATOL S receive 2.11 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SHAHNAN SHAH, KHATOL S is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +60.7% benefit to allowance rate for applications examined by SHAHNAN SHAH, KHATOL S. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.4% of applications are subsequently allowed. This success rate is in the 26% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 42.1% of cases where such amendments are filed. This entry rate is in the 57% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 114.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 79% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 85.4% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.3% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 5.2% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.7% of allowed cases (in the 52% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.